FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

Para fins de pesquisa apenas. Leia o disclaimer completo →

Biblioteca de Peptídeos

LL-37

Cathelicidin / Human Cathelicidin / hCAP-18

Immune & Thymic

LL-37 is the only human cathelicidin antimicrobial peptide, a 37-amino acid cationic peptide cleaved from its precursor protein hCAP-18 by proteinase 3 in neutrophils and various epithelial cells. It serves as a critical component of the innate immune system, providing broad-spectrum antimicrobial activity against bacteria, viruses, and fungi while also modulating inflammation and promoting wound healing. LL-37 expression is upregulated by vitamin D3, which mechanistically explains many of vitamin D's documented immune-enhancing effects.

Mecanismo de Ação

Endogenous human antimicrobial peptide cleaved from cathelicidin precursor hCAP-18. Disrupts microbial membranes, neutralizes endotoxin (LPS), modulates TLR signaling, promotes wound healing via angiogenesis, and recruits immune cells through chemotactic activity.

Protocolos de Pesquisa

Para fins de pesquisa apenas. Não é conselhos médicos.

Research protocols use 50-100mcg subcutaneously daily. Topical applications for wound healing at 10-50mcg/ml. Intranasal protocols studied for upper respiratory infections. Cycles of 1-4 weeks.

Notas de Pesquisa

Clinical Research Status

LL-37 is actively being investigated in clinical trials for chronic wound healing, with a Phase I/II trial (by Promore Pharma, now Lipigon) demonstrating safety and efficacy in venous leg ulcers. Research applications span chronic infections, biofilm-associated conditions, diabetic wound healing, and as a topical antimicrobial agent. No systemic injectable formulation has reached clinical trials due to challenges with peptide stability and potential hemolytic activity at high systemic concentrations. The connection between vitamin D deficiency and susceptibility to infections has driven research into LL-37 as the mechanistic link.

Key Published Findings

LL-37 demonstrates broad-spectrum antimicrobial activity against gram-positive and gram-negative bacteria, including MRSA and Pseudomonas aeruginosa, through membrane disruption mechanisms. A landmark 2006 Science paper showed LL-37 disrupts bacterial biofilms at sub-MIC concentrations by interfering with biofilm attachment and stimulating twitching motility. Research in the Journal of Immunology demonstrated LL-37 acts as a chemoattractant for neutrophils, monocytes, and T-cells through formyl peptide receptor-like 1 (FPRL1) activation. Studies show vitamin D supplementation increases LL-37 expression 3-5 fold in human macrophages, establishing a direct molecular link between vitamin D status and innate immunity.

Safety Profile

Topical application of LL-37 has been well-tolerated in clinical wound healing trials with no serious adverse events reported. At high systemic concentrations, LL-37 can exhibit cytotoxicity to mammalian cells and hemolytic activity, limiting its use as a systemic injectable. Local injection site reactions including redness and transient pain have been reported but resolve within hours. The peptide is rapidly degraded by serum proteases, which provides a natural safety mechanism against systemic accumulation but limits bioavailability.

Drug Interactions & Contraindications

High-dose vitamin D supplementation increases endogenous LL-37 production and may have additive effects when combined with exogenous LL-37 administration. Concurrent use with other membrane-active antimicrobials (daptomycin, polymyxins) could theoretically produce synergistic cytotoxicity requiring dose adjustment. Patients with rosacea or psoriasis may have elevated endogenous LL-37 levels contributing to their pathology, and exogenous administration could exacerbate these conditions. Not recommended for patients with systemic lupus erythematosus as LL-37-DNA complexes may activate plasmacytoid dendritic cells and worsen autoimmune responses.

Comparison to Related Compounds

Unlike conventional antibiotics, LL-37 kills bacteria through physical membrane disruption, making resistance development extremely difficult compared to target-specific drugs. Compared to other antimicrobial peptides (defensins, magainins), LL-37 is unique in its additional immunomodulatory, angiogenic, and wound-healing properties beyond direct microbial killing. Relative to KPV (another immune peptide), LL-37 is primarily antimicrobial and pro-healing while KPV is primarily anti-inflammatory. Its biofilm-disrupting properties distinguish it from virtually all conventional antibiotics, which are ineffective against established biofilms.

Community Observations

Users primarily employ LL-37 topically or via local subcutaneous injection near chronic wounds, infections, or biofilm-associated conditions at doses ranging from 50-200 mcg. Reports suggest benefit for chronic sinusitis, Lyme disease co-infections, and recurrent skin infections where biofilm involvement is suspected. Many users supplement with vitamin D3 (5,000-10,000 IU daily) to simultaneously boost endogenous LL-37 production alongside exogenous administration. The peptide is considered poorly suited for systemic injection due to rapid degradation and is most often used in targeted, localized applications.

Meio-Vivo

~4-6 hours

Reconstituição

Sterile water or bacteriostatic water

Armazenamento

Liofilizado

Store at -20C for long term.

Reconstituído

Refrigerate 2-8C. Use within 7 days.

Situação Legal nos EUA

Research chemical (not FDA-approved)

Também Conhecido Como

CathelicidinHuman CathelicidinhCAP-18

Perguntas frequentes

O que é LL-37?

LL-37 is the only human cathelicidin antimicrobial peptide, a 37-amino acid cationic peptide cleaved from its precursor protein hCAP-18 by proteinase 3 in neutrophils and various epithelial cells. It serves as a critical component of the innate immune system, providing broad-spectrum antimicrobial activity against bacteria, viruses, and fungi while also modulating inflammation and promoting wound healing. LL-37 expression is upregulated by vitamin D3, which mechanistically explains many of vitamin D's documented immune-enhancing effects.

Como LL-37 funciona?

Endogenous human antimicrobial peptide cleaved from cathelicidin precursor hCAP-18. Disrupts microbial membranes, neutralizes endotoxin (LPS), modulates TLR signaling, promotes wound healing via angiogenesis, and recruits immune cells through chemotactic activity.

Qual é o status regulatório de LL-37 nos EUA?

Research chemical (not FDA-approved)

Qual é a meia-vida de LL-37?

~4-6 hours

Por quais outros nomes LL-37 é conhecido?

Cathelicidin, Human Cathelicidin, hCAP-18

Peptide Contacts fornece resumos baseados em pesquisas apenas para fins informativos. Não hospedamos, distribuímos ou endossamos documentação de fornecedores. Todas as certificações de análise completa, certificados GMP e comunicações de fornecedores devem ser solicitadas e verificadas diretamente pelo comprador. Nada nesta plataforma constitui conselhos legais, médicos ou profissionais. Os usuários são unicamente responsáveis por verificar as credenciais dos fornecedores e garantir a conformidade com todas as leis locais, estaduais e federais aplicáveis antes de adquirir qualquer química de pesquisa. O uso desta plataforma constitui aceitação plena da responsabilidade pessoal.

Leia a declaração completa